Abiraterone
The serum concentration of Ipratropium bromide can be increased when it is combined with Abiraterone.
abobotulinumtoxinA
Ipratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.
Acetyl Sulfisoxazole
The metabolism of Ipratropium bromide can be decreased when combined with Acetyl sulfisoxazole.
Advertisement
Aclidinium
Ipratropium bromide may increase the anticholinergic activities of Aclidinium.
Alfentanil
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Alfentanil.
Alphaprodine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Alphaprodine.
Advertisement
Ambenonium
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Ambenonium.
Amiodarone
The metabolism of Ipratropium bromide can be decreased when combined with Amiodarone.
Amoxapine
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Amoxapine.
Advertisement
Apalutamide
The serum concentration of Ipratropium bromide can be decreased when it is combined with Apalutamide.
Aprepitant
The serum concentration of Ipratropium bromide can be increased when it is combined with Aprepitant.
Artemether
The metabolism of Ipratropium bromide can be decreased when combined with Artemether.
Atazanavir
The metabolism of Ipratropium bromide can be decreased when combined with Atazanavir.
Atomoxetine
The metabolism of Ipratropium bromide can be decreased when combined with Atomoxetine.
Atracurium
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Atracurium.
Atracurium Besylate
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Atracurium besylate.
Atropine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Atropine.
Benactyzine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Benactyzine.
Bendroflumethiazide
The serum concentration of Bendroflumethiazide can be increased when it is combined with Ipratropium bromide.
Benzthiazide
The serum concentration of Benzthiazide can be increased when it is combined with Ipratropium bromide.
Benztropine
The risk or severity of adverse effects can be increased when Benzatropine is combined with Ipratropium bromide.
Betaxolol
The metabolism of Ipratropium bromide can be decreased when combined with Betaxolol.
Biperiden
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Biperiden.
Boceprevir
The metabolism of Ipratropium bromide can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Ipratropium bromide can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Ipratropium bromide can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Ipratropium bromide can be decreased when it is combined with Bosentan.
Botulinum Toxin Type A
Ipratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.
Buprenorphine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Buprenorphine.
Bupropion
The metabolism of Ipratropium bromide can be decreased when combined with Bupropion.
Butorphanol
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Butorphanol.
Butylscopolamine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Butylscopolamine.
Carbamazepine
The metabolism of Ipratropium bromide can be increased when combined with Carbamazepine.
Celecoxib
The metabolism of Ipratropium bromide can be decreased when combined with Celecoxib.
Ceritinib
The serum concentration of Ipratropium bromide can be increased when it is combined with Ceritinib.
Chloroquine
The metabolism of Ipratropium bromide can be decreased when combined with Chloroquine.
Chlorothiazide
The serum concentration of Chlorothiazide can be increased when it is combined with Ipratropium bromide.
Chlorphenoxamine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Chlorphenoxamine.
Chlorpromazine
The metabolism of Ipratropium bromide can be decreased when combined with Chlorpromazine.
Chlorthalidone
The serum concentration of Chlorthalidone can be increased when it is combined with Ipratropium bromide.
Cholecalciferol
The metabolism of Ipratropium bromide can be decreased when combined with Cholecalciferol.
Cimetidine
The metabolism of Ipratropium bromide can be decreased when combined with Cimetidine.
Cinacalcet
The metabolism of Ipratropium bromide can be decreased when combined with Cinacalcet.
Citalopram
The metabolism of Ipratropium bromide can be decreased when combined with Citalopram.
Clarithromycin
The metabolism of Ipratropium bromide can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Ipratropium bromide can be decreased when combined with Clemastine.
Clobazam
The metabolism of Ipratropium bromide can be decreased when combined with Clobazam.
Clomipramine
The metabolism of Ipratropium bromide can be decreased when combined with Clomipramine.
Clotrimazole
The metabolism of Ipratropium bromide can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Ipratropium bromide can be decreased when combined with Clozapine.
Cobicistat
The serum concentration of Ipratropium bromide can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Ipratropium bromide can be decreased when combined with Cocaine.
Codeine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Codeine.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Codeine.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Codeine.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Ipratropium bromide.
Crizotinib
The metabolism of Ipratropium bromide can be decreased when combined with Crizotinib.
Curcumin
The metabolism of Ipratropium bromide can be decreased when combined with Curcumin.
Cyclopenthiazide
The serum concentration of Cyclopenthiazide can be increased when it is combined with Ipratropium bromide.
Cyclopentolate
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Cyclopentolate.
Cyclosporine
The metabolism of Ipratropium bromide can be decreased when combined with Cyclosporine.
Dabrafenib
The serum concentration of Ipratropium bromide can be decreased when it is combined with Dabrafenib.
Darifenacin
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Darifenacin.
Darunavir
The serum concentration of Ipratropium bromide can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Ipratropium bromide can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Ipratropium bromide can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Ipratropium bromide can be decreased when it is combined with Deferasirox.
Delavirdine
The metabolism of Ipratropium bromide can be decreased when combined with Delavirdine.
Demecarium
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Demecarium.
Desipramine
The metabolism of Ipratropium bromide can be decreased when combined with Desipramine.
Desloratadine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Desloratadine.
Dexetimide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dexetimide.
Dextromoramide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dezocine.
Dicyclomine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dicyclomine.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydrocodeine.
Dihydroergotamine
The metabolism of Ipratropium bromide can be decreased when combined with Dihydroergotamine.
Diltiazem
The metabolism of Ipratropium bromide can be decreased when combined with Diltiazem.
Diphenhydramine
The metabolism of Ipratropium bromide can be decreased when combined with Diphenhydramine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Diphenoxylate.
Dipivefrin
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Dipivefrin.
Distigmine
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Distigmine.
Donepezil
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Donepezil.
Dothiepin
The metabolism of Ipratropium bromide can be decreased when combined with Dosulepin.
Doxycycline
The metabolism of Ipratropium bromide can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Ipratropium bromide can be decreased when combined with Doxycycline.
Dronedarone
The metabolism of Ipratropium bromide can be decreased when combined with Dronedarone.
Duloxetine
The metabolism of Ipratropium bromide can be decreased when combined with Duloxetine.
Echothiophate
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Echothiophate.
Edrophonium
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Edrophonium.
Eliglustat
The metabolism of Ipratropium bromide can be decreased when combined with Eliglustat.
Eluxadoline
Ipratropium bromide may increase the constipating activities of Eluxadoline.
Enzalutamide
The serum concentration of Ipratropium bromide can be decreased when it is combined with Enzalutamide.
Erythromycin
The metabolism of Ipratropium bromide can be decreased when combined with Erythromycin.
Ethylmorphine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ethylmorphine.
Fentanyl
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fentanyl.
Fesoterodine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fesoterodine.
Flavoxate
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Flavoxate.
Flavoxate Hydrochloride
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Flavoxate.
Fluconazole
The metabolism of Ipratropium bromide can be decreased when combined with Fluconazole.
Fluoxetine
The metabolism of Ipratropium bromide can be decreased when combined with Fluoxetine.
Fluvoxamine
The metabolism of Ipratropium bromide can be decreased when combined with Fluvoxamine.
Fosamprenavir
The metabolism of Ipratropium bromide can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Ipratropium bromide can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The metabolism of Ipratropium bromide can be increased when combined with Fosphenytoin.
Fusidate
The serum concentration of Ipratropium bromide can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Ipratropium bromide can be increased when it is combined with Fusidic Acid.
Galantamine
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Gallamine Triethiodide.
Ginkgo biloba extract
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Ginkgo biloba.
Glucagon
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Glucagon recombinant.
glucagon (rDNA)
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Glucagon recombinant.
Glycopyrronium
Ipratropium bromide may increase the anticholinergic activities of Glycopyrronium.
Haloperidol
The metabolism of Ipratropium bromide can be decreased when combined with Haloperidol.
Heroin
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Heroin.
Homatropine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Homatropine.
Human Secretin
The therapeutic efficacy of Human secretin can be decreased when used in combination with Ipratropium bromide.
Hydrochlorothiazide
The serum concentration of Hydrochlorothiazide can be increased when it is combined with Ipratropium bromide.
Hydrocodone
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydrocodone.
HYDROCODONE POLISTIREX
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydrocodone.
Hydroflumethiazide
The serum concentration of Hydroflumethiazide can be increased when it is combined with Ipratropium bromide.
Hydromorphone
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydromorphone.
Hyoscyamine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hyoscyamine.
Hypoxis hemerocallidea root extract
The serum concentration of Ipratropium bromide can be decreased when it is combined with St. John's Wort.
Idelalisib
The metabolism of Ipratropium bromide can be decreased when combined with Idelalisib.
Imatinib
The metabolism of Ipratropium bromide can be decreased when combined with Imatinib.
Imipramine
The metabolism of Ipratropium bromide can be decreased when combined with Imipramine.
incobotulinumtoxinA
Ipratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.
Indapamide
The serum concentration of Indapamide can be increased when it is combined with Ipratropium bromide.
Indinavir
The metabolism of Ipratropium bromide can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Ipratropium bromide can be decreased when combined with Indinavir.
Isavuconazole
The serum concentration of Ipratropium bromide can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Ipratropium bromide can be decreased when combined with Isavuconazonium.
Isoflurophate
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Isoflurophate.
Isoniazid
The metabolism of Ipratropium bromide can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Ipratropium bromide can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Ipratropium bromide can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Ipratropium bromide can be increased when it is combined with Ivacaftor.
Ketoconazole
The metabolism of Ipratropium bromide can be decreased when combined with Ketoconazole.
Levomethadyl
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levomethadyl Acetate.
Levorphanol
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levorphanol.
Lopinavir
The metabolism of Ipratropium bromide can be decreased when combined with Lopinavir.
Lorcaserin
The metabolism of Ipratropium bromide can be decreased when combined with Lorcaserin.
Lovastatin
The metabolism of Ipratropium bromide can be decreased when combined with Lovastatin.
Loxapine
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Loxapine.
Luliconazole
The serum concentration of Ipratropium bromide can be increased when it is combined with Luliconazole.
Lumacaftor
The metabolism of Ipratropium bromide can be increased when combined with Lumacaftor.
Lumefantrine
The metabolism of Ipratropium bromide can be decreased when combined with Lumefantrine.
Malathion
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Malathion.
Manidipine
The metabolism of Ipratropium bromide can be decreased when combined with Manidipine.
Mecamylamine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mecamylamine.
Mefloquine
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Mefloquine.
Memantine
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Memantine.
Meperidine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pethidine.
Methadone
The metabolism of Ipratropium bromide can be decreased when combined with Methadone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methadyl Acetate.
Methantheline
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methantheline.
Methixene
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Metixene.
Methotrimeprazine
The metabolism of Ipratropium bromide can be decreased when combined with Methotrimeprazine.
Methscopolamine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methscopolamine.
Methscopolamine Bromide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methylscopolamine bromide.
Methyclothiazide
The serum concentration of Methyclothiazide can be increased when it is combined with Ipratropium bromide.
Metoclopramide
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Metoclopramide.
Metolazone
The serum concentration of Metolazone can be increased when it is combined with Ipratropium bromide.
Metoprolol
The metabolism of Ipratropium bromide can be decreased when combined with Metoprolol.
Mianserin
Mianserin may increase the anticholinergic activities of Ipratropium bromide.
Midostaurin
The metabolism of Ipratropium bromide can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Ipratropium bromide can be increased when it is combined with Mifepristone.
Minaprine
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Minaprine.
Mirabegron
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mirabegron.
Mitotane
The serum concentration of Ipratropium bromide can be decreased when it is combined with Mitotane.
Morphine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Morphine.
Nabilone
Ipratropium bromide may increase the tachycardic activities of Nabilone.
Nalbuphine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Nalbuphine.
Nefazodone
The metabolism of Ipratropium bromide can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Ipratropium bromide can be decreased when combined with Nelfinavir.
Neostigmine
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Neostigmine.
Netupitant
The serum concentration of Ipratropium bromide can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Ipratropium bromide can be increased when combined with Nevirapine.
Nicardipine
The metabolism of Ipratropium bromide can be decreased when combined with Nicardipine.
Nilotinib
The metabolism of Ipratropium bromide can be decreased when combined with Nilotinib.
Normethadone
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Normethadone.
O-PHENANTHROLINE
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with 1,10-Phenanthroline.
Octotropine Methylbromide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Anisotropine Methylbromide.
Octylonium
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Otilonium.
Olaparib
The metabolism of Ipratropium bromide can be decreased when combined with Olaparib.
onabotulinumtoxinA
Ipratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.
Opium
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Opium.
Orphenadrine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Orphenadrine.
Osimertinib
The serum concentration of Ipratropium bromide can be increased when it is combined with Osimertinib.
Oxitropium
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxitropium.
Oxybutynin
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxybutynin.
Oxycodone
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxycodone.
Oxymorphone
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxymorphone.
Oxyphenonium
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxyphenonium.
Palbociclib
The serum concentration of Ipratropium bromide can be increased when it is combined with Palbociclib.
Pancuronium
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pancuronium.
Pancuronium Bromide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pancuronium.
Panobinostat
The serum concentration of Ipratropium bromide can be increased when it is combined with Panobinostat.
Paregoric
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Morphine.
Paroxetine
The metabolism of Ipratropium bromide can be decreased when combined with Paroxetine.
Peginterferon Alfa-2b
The serum concentration of Ipratropium bromide can be decreased when it is combined with Peginterferon alfa-2b.
Pentazocine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pentazocine.
Pentobarbital
The metabolism of Ipratropium bromide can be increased when combined with Pentobarbital.
Phenobarbital
The metabolism of Ipratropium bromide can be increased when combined with Phenobarbital.
Phenytoin
The metabolism of Ipratropium bromide can be increased when combined with Phenytoin.
Physostigmine
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Physostigmine.
Pipecuronium
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pipecuronium.
Pirenzepine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pirenzepine.
Pirinitramide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Piritramide.
Polythiazide
The serum concentration of Polythiazide can be increased when it is combined with Ipratropium bromide.
Posaconazole
The metabolism of Ipratropium bromide can be decreased when combined with Posaconazole.
Potassium Chloride
Ipratropium bromide may increase the ulcerogenic activities of Potassium Chloride.
Pramlintide
Pramlintide may increase the anticholinergic activities of Ipratropium bromide.
Primidone
The metabolism of Ipratropium bromide can be increased when combined with Primidone.
Procyclidine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Procyclidine.
Profenamine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ethopropazine.
Promazine
The metabolism of Ipratropium bromide can be decreased when combined with Promazine.
Propantheline
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Propantheline.
Propantheline Bromide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Propantheline.
Propiverine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Propiverine.
Propoxyphene
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dextropropoxyphene.
Pyridostigmine
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Pyridostigmine.
Pyridostigmine Bromide
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Pyridostigmine.
Quinethazone
The serum concentration of Quinethazone can be increased when it is combined with Ipratropium bromide.
Quinidine
The metabolism of Ipratropium bromide can be decreased when combined with Quinidine.
Quinine
The metabolism of Ipratropium bromide can be decreased when combined with Quinine.
Ranolazine
The metabolism of Ipratropium bromide can be decreased when combined with Ranolazine.
Remifentanil
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Remifentanil.
Rifabutin
The metabolism of Ipratropium bromide can be increased when combined with Rifabutin.
Rifampin
The metabolism of Ipratropium bromide can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Ipratropium bromide can be increased when combined with Rifapentine.
rimabotulinumtoxinB
Ipratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type B.
Ritonavir
The metabolism of Ipratropium bromide can be decreased when combined with Ritonavir.
Rivastigmine
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Rivastigmine.
Rolapitant
The metabolism of Ipratropium bromide can be decreased when combined with Rolapitant.
Ropinirole
The metabolism of Ipratropium bromide can be decreased when combined with Ropinirole.
Rucaparib
The metabolism of Ipratropium bromide can be decreased when combined with Rucaparib.
Saquinavir
The metabolism of Ipratropium bromide can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Ipratropium bromide can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Sarilumab.
Scopolamine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine.
Secretin
The therapeutic efficacy of Secretin can be decreased when used in combination with Ipratropium bromide.
Sertraline
The metabolism of Ipratropium bromide can be decreased when combined with Sertraline.
Sildenafil
The metabolism of Ipratropium bromide can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Ipratropium bromide can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Ipratropium bromide can be increased when it is combined with Simeprevir.
Solifenacin
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Solifenacin.
ST. JOHN'S WORT EXTRACT
The serum concentration of Ipratropium bromide can be decreased when it is combined with St. John's Wort.
Sufentanil
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Sufentanil.
Sulfisoxazole
The metabolism of Ipratropium bromide can be decreased when combined with Sulfisoxazole.
Sulpiride
Ipratropium bromide may increase the anticholinergic activities of Sulpiride.
Tacrine
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Tacrine.
Tapentadol
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tapentadol.
Telaprevir
The metabolism of Ipratropium bromide can be decreased when combined with Telaprevir.
Telithromycin
The metabolism of Ipratropium bromide can be decreased when combined with Telithromycin.
Terbinafine
The metabolism of Ipratropium bromide can be decreased when combined with Terbinafine.
Tetrahydrocannabinol
Ipratropium bromide may increase the tachycardic activities of Dronabinol.
Thioridazine
The metabolism of Ipratropium bromide can be decreased when combined with Thioridazine.
Ticlopidine
The metabolism of Ipratropium bromide can be decreased when combined with Ticlopidine.
Tiotropium
Ipratropium bromide may increase the anticholinergic activities of Tiotropium.
Tipranavir
The metabolism of Ipratropium bromide can be decreased when combined with Tipranavir.
Tocilizumab
The serum concentration of Ipratropium bromide can be decreased when it is combined with Tocilizumab.
Tolterodine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tolterodine.
Topiramate
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Topiramate.
Tramadol
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tramadol.
Tranylcypromine
The metabolism of Ipratropium bromide can be decreased when combined with Tranylcypromine.
Trichlormethiazide
The serum concentration of Trichlormethiazide can be increased when it is combined with Ipratropium bromide.
Trihexyphenidyl
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trihexyphenidyl.
Trihexyphenidyl Hydrochloride
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trihexyphenidyl.
Trimethaphan
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trimethaphan.
Tropicamide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tropicamide.
Trospium
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trospium.
Tubocurarine
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tubocurarine.
Tyrothricin
The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Tyrothricin.
Umeclidinium
Ipratropium bromide may increase the anticholinergic activities of Umeclidinium.
Vecuronium
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Vecuronium.
Vemurafenib
The serum concentration of Ipratropium bromide can be decreased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Ipratropium bromide can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Ipratropium bromide can be decreased when combined with Verapamil.
Voriconazole
The metabolism of Ipratropium bromide can be decreased when combined with Voriconazole.
Ziprasidone
The metabolism of Ipratropium bromide can be decreased when combined with Ziprasidone.
